Direct cellular delivery of human proteasomes to delay tau aggregation

87Citations
Citations of this article
93Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The 26S proteasome is the primary machinery that degrades ubiquitin (Ub)-conjugated proteins, including many proteotoxic proteins implicated in neurodegeneraton. It has been suggested that the elevation of proteasomal activity is tolerable to cells and may be beneficial to prevent the accumulation of protein aggregates. Here we show that purified proteasomes can be directly transported into cells through mesoporous silica nanoparticle-mediated endocytosis. Proteasomes that are loaded onto nanoparticles through non-covalent interactions between polyhistidine tags and nickel ions fully retain their proteolytic activity. Cells treated with exogenous proteasomes are more efficient in degrading overexpressed human tau than endogenous proteasomal substrates, resulting in decreased levels of tau aggregates. Moreover, exogenous proteasome delivery significantly promotes cell survival against proteotoxic stress caused by tau and reactive oxygen species. These data demonstrate that increasing cellular proteasome activity through the direct delivery of purified proteasomes may be an effective strategy for reducing cellular levels of proteotoxic proteins.

Cite

CITATION STYLE

APA

Han, D. H., Na, H. K., Choi, W. H., Lee, J. H., Kim, Y. K., Won, C., … Lee, M. J. (2014). Direct cellular delivery of human proteasomes to delay tau aggregation. Nature Communications, 5. https://doi.org/10.1038/ncomms6633

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free